Zydus Cadila receives tentative US FDA nod for Pimavanserin capsules
Published 04 Jan, 2022
By Staff Reporter
Zydus Cadila’s US subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the FDA to market Pimavanserin Capsules in the strength of 34 mg, the pharma company said on Friday.